Fundraising Fox

Dracenpharma

Baltimore, US · Founded 2016 · 3 known investors

dracenpharma.com ↗

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.

BiotechHealthtech

Founders & leadership

DP
Drew Pardoll, M.D., Ph.D.Director
TM
Thomas M. EstokChief Executive Officer, President and Treasurer
AR
Asher RubinSecretary
RJ
Robert JacksonDirector
RW
Robert WildCo-founder & Chief Scientific Officer
JL
Jonathan LeffDirector

Investors · 3

Biotech Investments S.R.OPrague
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Deerfield Management CompanyreportedNew Yorkvia Jonathan Leff · board

Reported raises · per SEC filings

Form D private placements
▶$2.3MraisedAug 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Asher RubinExecutive Officer
  • Drew Pardoll, M.D., Ph.D.Director
  • Dennis M. BilskiExecutive Officer
  • Jonathan LeffDirector
Offering amount
$2.8M
Amount sold
$2.3M
Minimum investment
$2.7K
Proceeds to insiders
$45K
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.6MraisedNov 2021 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Asher RubinExecutive Officer
  • Dennis BilskiExecutive Officer
  • Thomas M. EstokExecutive Officer, Director
  • Drew Pardoll, M.D., Ph.D.Director
  • Jonathan LeffDirector
Offering amount
$17M
Amount sold
$8.6M
First sale
Nov 2021
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.5MraisedJan 2018 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Drew Pardoll, M.D., Ph.D.Director
  • Thomas M. EstokExecutive Officer, Director
  • Jonathan LeffDirector
  • Asher RubinExecutive Officer
  • Robert JacksonDirector
Offering amount
$40.5M
Amount sold
$8.5M
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.